Adage Capital Partners
CTNM

Adage Capital Partners’s Contineum Therapeutics CTNM Stock Holding History

Adage Capital Partners’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38M Buy
+328,000
New +$4.3M 0.01% 802
2025
Q1 		– Sell
-200,000
Closed -$2.93M – 956
2024
Q4 		$2.93M Hold
200,000
– – 0.01% 768
2024
Q3 		$3.83M Sell
200,000
-95,000
-32% -$1.82M 0.01% 739
2024
Q2 		$5.19M Buy
+295,000
New +$4.75M 0.01% 710

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners's CTNM Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 328,000 shares worth $5.38M. The stake represents 0.01% of the portfolio and ranks #802 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in CTNM as recently as Q4 2024.

Adage Capital Partners first reported a position in CTNM in Q2 2024 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Adage Capital Partners held 328,000 shares of Contineum Therapeutics worth $5.38M as of Q2 2026.
  • Contineum Therapeutics was a new Adage Capital Partners position in Q2 2026.
  • Contineum Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #802 holding.
  • Adage Capital Partners first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.